Depression in Parkinson's disease

European Journal of Neurology

Volumn 9, Issue SUPPL. 3, 2002, Pages 44-54

  Burn, D J ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aetiology; Clinical features; Depression; Epidemiology; Parkinson's disease; Treatment

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PERGOLIDE; PRAMIPEXOLE; REBOXETINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELUSION; DEPRESSION; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DRUG FEVER; HAMILTON SCALE; HEADACHE; HOMEOSTASIS; HUMAN; HYPERREFLEXIA; HYPOMANIA; MENTAL INSTABILITY; MOOD DISORDER; MOTOR DYSFUNCTION; MYOCLONUS; NAUSEA; NORADRENERGIC SYSTEM; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; QUALITY OF LIFE; RATING SCALE; REVIEW; SCREENING; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; STUPOR; SWEATING; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; TREMOR; URINE RETENTION;

ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMANS; MOOD DISORDERS; NERVE NET; PARKINSON DISEASE; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0036460170     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.9.s3.6.x     Document Type: Review

References (115)

1. Alexander GE, Crutcher MD, DeLong MR (1990). Basal ganglia-thalamocortical circuits: Parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Prog Brain Res 85:119-146.
2. Allain H, Schuck S, Mauduit N (2000). Depression in Parkinson's disease. Br Med J 320:1287-1288.
3. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE (1980). Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurolologica Scand 62:210-219.
4. Armin S, Andreas H, Hermann W, Eckard K, Wolfgang G, Otto B (1997). Pramipexole, a dopamine agonist, in major depression: Antidepressant effects and tolerability in an open-label study with multiple doses. Clin Neuropharmacol 20:S36-S45.
5. Arsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E (1999). Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatric Psychiatry 14:866-874.
6. Asnis G (1977). Parkinson's disease, depression, and ECT. A review and case study. Am J Psychiatry 134:191-195.
7. Beekman ATF (1999). Diagnostic procedures in depression in Parkinson's disease. In: Wolters EC, Scheltens P, Berendse HW, eds. Mental Dysfunction in Parkinson's Disease, Vol. 2. Academic Pharmaceutical Productions, Utrecht, pp. 263-271.
8. Bejjani BP, Damier P, Arnulf I et al. (1999). Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 340:1476-1480.
9. Berg D, Supprian T, Hofmann E et al. (1999). Depression in Parkinson's disease: Brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol 246:1186-1193.
10. Birkmayer W (1983). Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurolologica Scandonavica 95:103-106.
11. Brown R, Jahanshahi M (1995). Depression in Parkinson's disease: A psychosocial viewpoint. Adv Neurol 65:61-84.
12. Brown RG, MacCarthy B, Der Gotham AMGJ, Marsden CD (1988). Depression and disability in Parkinson's disease: A follow-up of 132 cases. Psychol Med 18:49-55.
13. Brown RG, MacCarthy B, Jahanshahi M, Marsden CD (1989). Accuracy of self-reported disability in patients with parkinsonism. Arch Neurol 46:955-959.
14. Caley CF, Friedman JH (1992). Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 53:278-282.
15. Cantello R, Aguggia M, Gilli M et al. (1989). Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: Possible role of the 'hedonic' dopamine synapse. J Neurol, Neurosurgery Psychiatry 52:724-731.
16. Cantello R, Gilli M, Riccio A, Bergamasco B (1986). Mood changes associated with 'end of dose deterioration' in Parkinson's disease: A controlled study. J Neurol, Neurosurgery Psychiatry 49:1182-1190.
17. Celesia GG, Wanamaker WM (1972). Psychiatric disturbances in Parkinson's disease. Dis Nervous System 33:577-583.
18. Chan-Palav V, Asan E (1989). Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comparative Neurol 287:373-392.
19. Charlton CG (1997). Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: A model that may explain the occurrence of depression in Parkinson's disease. Life Sci 61:495-502.
20. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV (1991). Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 114:2095-2122.
21. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000). Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression Anxiety 11:58-65.
22. Cote L (1999). Depression. Impact and management by the patient and family. Neurology 52:S7-S9.
23. Cummings JL (1992). Depression and Parkinson's disease: A review. Am J Psychiatry 149:443-454.
24. Cummings JL, Masterman DL (1999). Depression in patients with Parkinson's disease. Int J Geriatric Psychiatry 14:711-718.
25. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999). The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122:1437-1448.
26. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2000). Brain serotonin 1A receptors in Parkinson's disease with and without depression measured by positron emission tomography with 11C-WAY 100635. Movement Disorders 15:213.
27. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R (1992). An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 49:305-307.
28. Douyon R, Serby M, Klutchko B, Rotrosen J (1990). ECT and Parkinson's disease revisited: A 'naturalistic' study. Am J Psychiatry 146:1451-1455.
29. Dysken M, Evans HM, Chan CH, Davis JM (1976). Improvement of depression and parkinsonism during ECT: A case study. Neuropsychobiology 2:81-86.
30. Edwards JG, Anderson I (1999). Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-533.
31. Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ (1990). Depressive symptoms in Parkinson's disease: A comparison with disabled control subjects. J Geriatric Psychiatry Neurol 3:3-9.
32. Fava M, Rosenbaum JF, Kolsky AR et al. (1999). PEN study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol 19:329-335.
33. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ (2000). Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol, Neurosurgery Psychiatry 68:423-428.
34. Global Parkinson's Disease Survey Steering Committee (2002). Factors impacting on quality of life in Parkinson's disease: Results from an international study. Movement Disorders 17:60-67.
35. Goetz CG, Tanner CM, Klawans HL (1984). Bupropion in Parkinson's disease. Neurology 34:1092-1094.
36. Gotham A-M, Brown RG, Marsden CD (1986). Depression in Parkinson's disease: A quantitative and qualitative analysis. J Neurol, Neurosurgery Psychiatry 49:381-389.
37. Hantz P, Caradoc-Davies G, Caradoc-Davies T, Weatherall M, Dixon G (1994). Depression in Parkinson's disease. Am J Psychiatry 151:1010-1014.
38. Henderson R, Kurlan R, Kersun JM, Como P (1992). Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neuroscience 4:257-264.
39. Hinds NP, Hillier CE, Wiles CM (2000). Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol 247:811.
40. Hobson P, Holden A, Meara J (1999). Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire. Age Ageing 28:341-346.
41. Huber TJ, Dietrich DE, Emrich HM (1999). Possible use of amantadine in depression. Pharmacopsychiatry 32:47-55.
42. Huber SJ, Paulson GW, Shuttleworth EC (1988). Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease. J Neurol, Neurosurgery Psychiatry 51:855-858.
43. Hughes TA, Ross HF, Musa S et al. (2000). A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54:1596-1602.
44. Izumi T, Inoue T, Kitigawa N et al. (2000). Open pergolide treatment of tricyclic and heterocyclic-resistant depression. J Affective Disorders 61:127-132.
45. Jankovic J, McDermott M, Carter J et al. (1990). Variable expression of Parkinson's disease: A baseline analysis of the DATATOP cohort. Neurology 40:1529-1534.
46. Jouvent R, Abensour P, Bonnet AM, Widlocher D, Agid Y, Lhermitte F (1983). Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison. J Affective Disorders 5:141-145.
47. Karlsen KH, Larsen JP, Tandberg E, Maeland JG (1999). Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol, Neurosurgery Psychiatry 66:431-435.
48. Klaasen T, Verhey FR, Sneijders GH, Rozendaal N, de Vet HC, van Praag HM (1995). Treatment of depression in Parkinson's disease: A meta-analysis. J Neuropsychiatry Clin Neuroscience 7:281-286.
49. Koob GF, Le Moal M (1997). Drug abuse: Hedonistic homeostatic dysregulation. Science 278:52-57.
50. Kostic VS, Djuricic BM, Covickovic-Sternic N, Bumbasirevic L, Nikolic M, Mrsulja BB (1987). Depression and Parkinson's disease: Possible role of serotonergic mechanisms. J Neurol 234:94-96.
51. Kuhn W, Muller T, Gerlach M et al. (1996). Depression in Parkinson's disease: Biogenic amines in CSF of 'de novo' patients. J Neural Transmission 103:1441-1445.
52. Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK (2000). The quality of life in Parkinson's disease. Movement Disorders 15:216-223.
53. Laitinen L (1969). Desipramine in treatment of Parkinson's disease. A placebo-controlled study. Acta Neurologica Scand 45:109-113.
54. Lane RM (1998). SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment. J Psychopharmacol 12:192-214.
55. Larson JP, Tandberg E (2001). Sleep disorders in patients with Parkinson's disease: Epidemiology and management. CNS Drugs 15:267-275.
56. Lebensohn ZM, Jenkins RB (1975). Improvement of Parkinsonism in depressed patients treated with ECT. Am J Psychiatry 132:283-285.
57. Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink W (2000a). The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatric Psychiatry 15:644-649.
58. Leentjens AF, Verhey FR, Luijckx GJ, Troost J (2000b). The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Movement Disorders 15:1221-1224.
59. Leentjens AFG, Verhey FRJ, van Praag HM (1999). Selective serotonin reuptake inhibitors in the treatment of depression in Parkinson's disease: A review of available evidence concerning efficacy, side-effects and interactions. In: Wolters EC, Scheltens P, Berendse HW, eds. Mental Dysfunction in Parkinson's Disease, Vol. 2. Academic Pharmaceutical Productions, Utrecht, pp. 272-284.
60. Lemke MR (2000). Reboxetine treatment of depression in Parkinson's disease. J Clin Psychiatry 61:872.
61. Leonard BE (1999). Prevalence and psychopathology of depression in Parkinson's disease. In: Wolters EC, Scheltens P, Berendse HW, eds. Mental Dysfunction in Parkinson's Disease, Vol. 2. Academic Pharmaceutical Productions, Utrecht, pp. 248-253.
62. Levin BE, Llabre MM, Weiner WJ (1988). Parkinson's disease and depression: Psychometric properties of the Beck Depression Inventory. J Neurol, Neurosurgery Psychiatry 51:1401-1404.
63. Mahieux F, Fénelon G, Flahault A, Manifacier M-J, Michelet D, Bollet F (1998). Neuropsychological prediction of dementia in Parkinson's disease. J Neurol, Neurosurgery Psychiatry 64:178-183.
64. Mally J, Stone TW (1999a). Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. J Neurol Sci 162:179-184.
65. Mally J, Stone TW (1999b). Therapeutic and 'dose-dependent' effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson's disease. J Neuroscience Res 57:935-940.
66. Manes F, Jorge R, Morcuende M, Yamada T, Paradiso S, Robinson RG (2001). A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. Int Psychogeriatrics 13:225-231.
67. Maricle RA, Nutt JG, Valentine RJ, Carter JH (1995). Doserelationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study. Neurology 45:1757-1760.
68. Mayberg HS, Starkstein SE, Sadzot B et al. (1990). Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 28:57-64.
69. Mayeux R, Stern Y, Cote L, Williams JB (1984). Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34:642-646.
70. Mayeux R, Stern Y, Rosen J, Leventhal J (1981). Depression, intellectual impairment, and Parkinson disease. Neurology 31:645-650.
71. Mayeux R, Stern Y, Sano M, Williams JB, Cote LJ (1988). The relationship of serotonin to depression in Parkinson's disease. Movement Disorders 3:237-244.
72. Meara J, Mitchelmore E, Hobson P (1999). Use of the GDS15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 28:35-38.
73. Mendlewicz J (2001). Optimising antidepressant use in clinical practice: Towards criteria for antidepressant selection. Br J Psychiatry 179:S 1-S3.
74. Menza MA, Palermo B, DiPaola R, Sage JI, Ricketts MH (1999). Depression and anxiety in Parkinson's disease: Possible effect of genetic variation in the serotonin transporter. J Geriatric Psychiatry Neurol 12:49-52.
75. Menza MA, Robertson-Hoffman DE, Bonapace AS (1993). Parkinson's disease and anxiety: Comorbidity with depression. Biol Psychiatry 34:465-470.
76. Miller E, Berrios GE, Politynska BE (1996). Caring for someone with Parkinson's disease: Factors that contribute to distress. Int J Geriatric Psychiatry 11:263-268.
77. Moellentine C, Rummans T, Ahlskog JE et al. (1998). Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neuroscience 10:187-193.
78. Montastruc J-L, Fabre N, Blin O, Senard J-M, Rascol O, Rascol A (1995). Does fluoxetine aggrevate Parkinson's disease? A pilot prospective study. Movement Disorders 10:355-357.
79. Mössner R, Henneberg A, Schmitt A et al. (2001). Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 6:350-352.
80. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD (1987). Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med 17:899-904.
81. Normann C, Hesslinger B, Frauenknecht S, Berger M, Walden J (1997). Psychosis during chronic levodopa therapy triggered by the new antidepressant mirtazapine. Pharmacopsychiatry 30:263-265.
82. Poewe W, Luginger E (1999). Depression in Parkinson's disease: Impediments to recognition and treatment options. Neurology 52:S2-S6.
83. Rektorova I, Rektor I, Hortova H et al. (2001). Depression in Parkinson's disease: An eight-month, randomised, openlabel, national, multi-centre comparative study of pramipexole and pergolide. Parkinsonism Related Disorders 7:S68.
84. Richard IH, Kurlan R and the Parkinson's Disease Study Group (1997a). A survey of antidepressant drug use in Parkinson's disease. Neurology 49:1168-1170.
85. Richard IH, Kurlan R, Tanner C et al. (1997b). Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 48:1070-1077.
86. Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ (1994). Depression in Parkinson's disease. A positron emission study. Br J Psychiatry 165:333-339.
87. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK (1989). Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26:47-50.
88. Rodriguez-Oroz MC, Gorospe A, Guridi J et al. (2000). Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neurology 55:S45-S51.
89. Rogers DC, Costall B, Domeney AM et al. (2000). Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology 151:91-95.
90. Sanchez-Ramos J (2002). The straight dope on addiction to dopaminergic drugs. Movement Disorders 17:223-225.
91. Santamaria J, Tolosa E, Valles A (1986). Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism. Neurology 36:1130-1133.
92. Sargent PA, Kjaer KH, Bench CJ et al. (2000). Brain serotonin 1A receptor binding measured by positron emission tomography with [llC]WAY-100635: Effects of depression and antidepressant treatment. Arch General Psychiatry 57:174-180.
93. Schrag A, Jahanshahi M, Quinn N (2000). What contributes to quality of life in patients with Parkinson's disease? J Neurol, Neurosurgery Psychiatry 69:308-312.
94. Shiba M, Bower JH, Maraganore DM et al. (2000). Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study. Movement Disorders 15:669-677.
95. Shulman LM, Taback RL, Bean J, Weiner WJ (2001). Comorbidity of the nonmotor symptoms of Parkinson's disease. Movement Disorders 16:507-510.
96. Sporn J, Ghaemi SN, Sambur MR et al. (2000). Pramipexole augmentation in the treatment of unipolar and bipolar depression: A retrospective chart review. Ann Clin Psychiatry 12:137-140.
97. Starkstein SE, Berthier ML, Bolduc PL, Preziosi TJ (1989). Depression in patients with early versus late onset of Parkinson's disease. Neurology 39:1441-1445.
98. Starkstein SE, Bolduc PL, Mayberg HS, Preziosi T J, Robinson RG (1990a). Cognitive impairments and depression in Parkinson's disease: A follow up study. J Neurol, Neurosurgery Psychiatry 53:597-602.
99. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ (1992). A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol, Neurosurgery Psychiatry 55:377-382.
100. Starkstein SE, Petracca G, Chemerinski E et al. (1998). Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord 13:29-33.
101. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990b). Depression in Parkinson's disease. J Nervous Mental Dis 178:27-31.
102. Starkstein SE, Preziosi TJ, Forrester AW, Robinson RG (1990c). Specificity of affective and autonomic symptoms of depression in Parkinson's disease. J Neurol, Neurosurgery Psychiatry 53:869-873.
103. Stern Y, Marder K, Tang MX, Mayeux R (1993). Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 43:1690-1692.
104. Strang RR (1965). Imipramine in treatment of Parkinsonism: A double-blind study. Br Med J 2:33-34.
105. Tandberg E, Larsen JP, Aarsland D, Cummings JL (1996). The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 53:175-179.
106. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL (1997). Risk factors for depression in Parkinson disease. Arch Neurol 54:625-630.
107. Taylor AE, Saint-Cyr JA, Lang AE, Kenny FT (1986). Parkinson's disease and depression: A critical re-evaluation. Brain 109:279-292.
108. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G (2000). Tolerability of paroxetine in Parkinson's disease: A prospective study. Movement Disorders 15:986-989.
109. Thomas MJ, Malenka RC, Bonci A (2000). Modulation of long-term depression by dopamine in the mesolimbic system. J Neuroscience 20:5581-5586.
110. Torack RM, Morris JC (1988). The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 45:497-501.
111. Troster AI, Stalp LD, Paolo AM, Fields JA, Koller WC (1995). Neuropsychological impairment in Parkinson's disease with and without depression. Arch Neurol 52:1164-1169.
112. Vogel H-P (1982). Symptoms of depression in Parkinson's disease. Pharmacopsychiatry 15:192-196.
113. Warburton JW (1967). Depressive symptoms in Parkinson patients referred for thalamotomy. J Neurol, Neurosurgery Psychiatry 30:368-370.
114. Wassermann EM, Lisanby SH (2001). Therapeutic application of repetitive transcranial magnetic stimulation: A review. Clin Neurophysiol 112:1367-1377.
115. Zangen A, Nakash R, Overstreet DH, Yadid G (2001). Association between depressive behaviour and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology 155:434-439.